0000000000455550

AUTHOR

F. Poletti

showing 3 related works from this author

Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016

2018

Objectives: The aim was to evaluate the evolution of transmitted HIV-1 drug resistance (TDR) prevalence in antiretroviral therapy (ART)-naïve patients from 2006 to 2016. Methods: HIV-1 sequences were retrieved from the Antiviral Response Cohort Analysis (ARCA) database and TDR was defined as detection of at least one mutation from the World Health Organization (WHO) surveillance list. Results: We included protease/reverse transcriptase sequences from 3573 patients; 455 had also integrase sequences. Overall, 68.1% of the patients were Italian, the median CD4 count was 348 cells/μL [interquartile range (IQR) 169–521 cells/μL], and the median viral load was 4.7 log 10 HIV-1 RNA copies/mL (IQR …

0301 basic medicineMaleantiretroviral therapy; HIV; recent HIV infection; resistance epidemiology; transmitted HIV drug resistance; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Female; HIV Infections; HIV-1; Humans; Italy; Male; Middle Aged; Mutation; Odds Ratio; Prevalence; Viral Proteins; Drug Resistance Viralantiretroviral therapy; HIV; recent HIV infection; resistance epidemiology; transmitted HIV drug resistance; Health Policy; Infectious Diseases; Pharmacology (medical)Drug ResistanceHIV InfectionsDrug resistanceGastroenterologyInterquartile rangeOdds RatioPrevalenceHIV InfectionPharmacology (medical)ViralbiologyHealth PolicyMiddle AgedIntegraseInfectious DiseasesItalyFemaleViral loadHumanresistance epidemiologyAdultmedicine.medical_specialtytransmitted HIV drug resistanceAnti-HIV AgentsHIV; antiretroviral therapy; recent HIV infection; resistance epidemiology; transmitted HIV drug resistance030106 microbiologyantiretroviral therapySettore MED/17 - MALATTIE INFETTIVEVirus03 medical and health sciencesrecent HIV infectionViral ProteinsInternal medicineDrug Resistance ViralmedicineViral ProteinHumansbusiness.industryAnti-HIV AgentHIVOdds ratioReverse transcriptaseConfidence intervalCD4 Lymphocyte CountMutationbiology.proteinHIV-1business
researchProduct

Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients

2019

Maleantiretroviral treatmentInfectious Disease TransmissiongenotypeHuman immunodeficiency virus (HIV)Drug ResistanceHIV InfectionsDrug resistancemedicine.disease_causeRetrospective StudieGenotypepol Gene Products Human Immunodeficiency ViruPrevalenceMedicineVerticalHIV InfectionViralpol Gene ProductsYoung adultGeneral MedicineInfectious DiseasesItalyMutation (genetic algorithm)FemaleHuman Immunodeficiency VirusHumanMicrobiology (medical)AdultSettore MED/17 - Malattie InfettiveAdolescentAnti-HIV AgentsYoung AdultAcquired resistanceDrug Resistance ViralHumansvertical HIV transmissionAdolescent; Adult; Anti-HIV Agents; Drug Resistance Viral; Female; HIV Infections; HIV-1; Humans; Italy; Male; Mutation; Prevalence; Retrospective Studies; Young Adult; pol Gene Products Human Immunodeficiency Virus; Infectious Disease Transmission VerticalRetrospective StudiesHIV perinatally infectionbusiness.industryAnti-HIV AgentRetrospective cohort studyVirologyInfectious Disease Transmission VerticalLarge cohortpol Gene Products Human Immunodeficiency VirusDrug resistanceMutationHIV-1Drug resistance; HIV-1; antiretroviral treatment; genotype; vertical HIV transmissionbusiness
researchProduct

Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis.

2012

Introduction: This study aimed at defining protease (PR) resistance mutations associated with darunavir (DRV) failure and PR resistance evolution at DRV failure in a large database of treatment-experienced human immunodeficiency virus (HIV) patients. Results: Overall, 1,104 patients were included: 118 (10.7%) failed at a median observation time of 16 months. The mean number of PR mutations at baseline was 2.7, but it was higher in patients who subsequently failed DRV. In addition, the number of PR mutations increased at failure. The increase in the mean number of mutations was completely related to mutations considered to be associated with DRV resistance following the indications of the ma…

MaleTime FactorsCross-sectional studyHuman immunodeficiency virus (HIV)Drug ResistanceHIV InfectionsDrug resistancemedicine.disease_causeCohort StudiesAntiretroviral Therapy Highly ActiveRitonavir-boosted darunavirGenotypeHIV InfectionTreatment FailureViralGenotypic resistanceDarunavirSulfonamidesGeneral MedicineMiddle AgedVirological failureInfectious DiseasesFemaleHumanmedicine.drugAdultMicrobiology (medical)Logistic ModelTime FactorGenotypeAntiretroviral TherapySettore MED/17 - MALATTIE INFETTIVESulfonamideDrug Resistance ViralmedicineHumansHighly ActiveDarunavir; Genotypic resistance; Protease inhibitors; Ritonavir-boosted darunavir; Adult; Antiretroviral Therapy Highly Active; Cohort Studies; Cross-Sectional Studies; Female; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Logistic Models; Male; Middle Aged; Mutation; Sulfonamides; Time Factors; Treatment Failure; Drug Resistance Viral; Microbiology (medical); Infectious DiseasesHIV Protease InhibitorDarunavirCross-Sectional Studiebusiness.industryHIV Protease InhibitorsProtease inhibitorsAntiretroviral therapyVirologyCross-Sectional StudiesLogistic ModelsProtease inhibitorMutationGenotypic resistanceHIV-1Cohort Studiebusiness
researchProduct